View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Exploring Current and Emerging Data Sets to Move Treatment of Ovarian Cancer Forward: A Focus on PARP Inhibition, Immunotherapy, and Beyond!

Exploring Current and Emerging Data Sets to Move Treatment of Ovarian Cancer Forward: A Focus on PARP Inhibition, Immunotherapy, and Beyond!

Wednesday, July 1, 2020

Live Webcast!: 8:00 PM – 10:00 PM ET


The therapeutic landscape for advanced ovarian cancer has undergone dramatic changes over the past year. During this educational program, experts in ovarian cancer management will discuss how they leverage key data sets toward use of state-of-the-art molecular testing strategies and to guide overall treatment planning, including therapeutic selection and sequencing and use of maintenance therapy. Best practices for using PARP inhibitors, including adverse event (AE) management, will be reviewed throughout the program. New standards of care and future directions in the field will also be considered in the context of recent data readouts, new systemic therapy indications, and highly anticipated trials. The case-based format will encourage sharing of best practices, evolving strategies, and clinical skills. Embedded Q&A sessions with the faculty will allow participants to seek guidance on challenges they face in their own practices.

Benefits of Attending

  • Interact with expert thought leaders in ovarian cancer
  • Analyze data from recent clinical trials in ovarian cancer and how these data may affect clinical practice
  • Identify potential opportunities to incorporate emerging treatments into the management of ovarian cancer
  • Optimize management strategies for patients with ovarian cancer

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Target Audience

This educational program is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate molecular testing and its application in selection of therapy for patients with newly diagnosed and recurrent ovarian cancer
  • Discuss the rationale for maintenance therapy in the management of ovarian cancer
  • Describe the efficacy and safety of PARP inhibitors in the setting of frontline and recurrent ovarian cancer
  • Identify strategies for the prevention, recognition, and management of AEs associated with new and emerging treatments for ovarian cancer

Program Chair

Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Director and Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By